In talks with multinational pharma cos for acquisition of brands: Bafna pharmaceuticals

​​The Earnings Before Interest Depreciation and Amortization (EBITDA) for the half year ending September 30, 2021 was at Rs 7.43 crore, as against Rs 4.28 crore registered in the same period of last financial year, the statement added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3Fv4AP9
via IFTTT